The study examined the intramedullary application of IlluminOss Medical’s light-curable photodynamic bone stabilization system. The system gained CE Mark approval and is commercially available in international markets. It combines the use of proven medical polymers and traditional balloon catheter technology.
“The data demonstrated that the photodynamic bone stabilization system did not disrupt bone formation when injected into intact bones, but did lead to increasing levels of cortical bone from eight to 26 weeks when used in the fracture gap,” said Brett G. Zani, PhD, director of applied sciences at CBSET and principal investigator.
CBSET, a not-for-profit preclinical research institute, published the efficacy data.
More articles on devices:
Symmetry Medical to close Indiana orthopedic implant facility
NuVasive CEO resigns after compliance investigation — 5 things to know
Orthofix stock gains big — 14%: 5 things to know
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
